C

California Medical Research Associates | Northridge, CA

Research site
(Unclaimed)
Location
18531 Roscoe Boulevard 206, Northridge, California, United States of America

Site insights

Top conditions

Top treatments

Mirikizumab
UPB-101
Estradiol
LY3298176
GDC-6599
Ustekinumab
Ensifentrine
Elagolix
ABX464
TAK-906

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 22 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical resp...

Active, not recruiting
Ulcerative Colitis
Drug: Placebo SC
Drug: Mirikizumab SC

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and...

Enrolling
Unexplained Chronic Cough
Chronic Refractory Cough (CRC) With Non-atopic Asthma
Other: GDC-6599-matching placebo
Diagnostic Test: Mannitol

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease.The purpose of this study is to find out whether BI 706321 co...

Active, not recruiting
Crohn Disease
Drug: ustekinumab
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Mirikizumab
Drug: Placebo

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease...

Enrolling
Celiac Disease
Dietary Supplement: Gluten
Drug: TAK-101

This is phase 3b study seeks to evaluate the safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menst...

Active, not recruiting
Uterine Fibroids
Heavy Menstrual Bleeding
Other: E2/NETA Placebo
Drug: E2/NETA

A randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years to...

Enrolling
Ulcerative Proctitis
Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
Combination Product: Twice daily placebo suppository administered with Sephure applicator

Trial sponsors

Lilly logo
AbbVie logo
A
Boehringer Ingelheim logo
CSL Behring logo
C
Genentech logo
J
M
Mylan logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems